The COVID-19 and Cancer Consortium (CCC19) Registry

In late 2019 and early 2020, the world witnessed the outbreak of respiratory disease caused by a novel coronavirus first detected in Wuhan, China, and now a pandemic. The virus has been named SARS-CoV-2, and the disease it causes, coronavirus disease 2019, abbreviated as COVID-19. There are now over 300,000 persons diagnosed with this disease around the world, and nearly 14,000 deaths.

Given this acute lack of knowledge and concern for extreme vulnerability, we formed a new consortium, the COVID-19 and Cancer Consortium (CCC19). The driving goal of the consortium is to collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals. No protected health information (PHI), as defined by the Health Insurance Portability and Accountability Act of 1996 (HIPAA), will be collected by this centralized registry.

Eligibility Criteria:

Healthcare providers or their proxies who would like to report a patient with ALL of the following criteria:

• Suspected (presumptive positive based on clinical presentation) or lab confirmed COVID-19.
• Current or past medical history of invasive malignancy (any type)

Available at: Hartford Hospital, Hospital of Central Connecticut and MidState Medical Center, Backus Hospital, Windham Hospital, Charlotte Hungerford, Saint Vincent’s Medical Center